Health Care & Life Sciences » Pharmaceuticals | Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
20,255.00
20,186.00
39,865.00
18,010.00
15,567.00
25,208
Depreciation, Depletion & Amortization
1,927.00
2,784.00
13,554.00
11,868.00
2,984.00
2,956
Other Funds
196.00
436.00
283.00
-
-
9,612
Funds from Operations
13,569.00
48,594.00
17,190.00
3,005.00
1,957.00
37,776
Changes in Working Capital
26,023.00
32,960.00
29,639.00
11,108.00
26.00
7,790
Net Operating Cash Flow
39,592.00
81,554.00
12,449.00
8,103.00
1,983.00
29,986
Capital Expenditures
176.00
8,769.00
2,527.00
1,407.00
1,664.00
Purchase/Sale of Investments
34,099.00
3,513.00
24,071.00
8,664.00
8,567.00
Net Investing Cash Flow
34,275.00
12,037.00
26,598.00
10,071.00
10,107.00
Net Financing Cash Flow
49,859.00
89,728.00
4,091.00
7,751.00
5,251.00
Net Change in Cash
24,008.00
3,863.00
10,058.00
10,417.00
6,799.00
Free Cash Flow
39,768.00
82,323.00
9,922.00
9,510.00
3,647.00
Deferred Taxes & Investment Tax Credit
-
-
-
104.00
-
-
Other Sources
-
245.00
-
-
124.00
Change in Capital Stock
50,055.00
90,164.00
4,374.00
7,751.00
5,251.00
Exchange Rate Effect
-
-
-
6.00
40.00

About Vanda Pharmaceuticals

View Profile
Address
2200 Pennsylvania Avenue NW
Washington District of Columbia 20037
United States
Employees -
Website http://www.vandapharma.com
Updated 07/08/2019
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.